PolyBio Research Foundation has launched a $1.35 million program at UCSF to compare and validate diagnostic tests for long COVID, aiming to address the lack of standardized clinical diagnostics in the field.
A peer-reviewed economic analysis challenges the assumption that erythrocyte sedimentation rate and C-reactive protein tests are interchangeable, finding that combined testing reduces misdiagnoses and lowers overall costs.
The BiliSeq molecular test detected bile duct cancer in 82% of cases—compared to 44% with standard pathology—according to a six-year, multi-institutional study.
The integration gives more than 4,700 oncology providers across 1,600-plus community cancer care centers direct access to order and receive results from multiple precision oncology tests within a single clinical workflow.
A new study validates a machine-learning platform that detects prostate cancer through biochemical patterns in urine samples.
